ACOR - Earnings announcements

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be

INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial results on Monday, November 13 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/728181174 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the

INBRIJA® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q2 2023 net revenue of $16.9 million, a 7% decrease from Q2 2022; FAMPYRA royalty revenue of $2.9 million 2023 INBRIJA U.S. net revenue, adjusted operating expenses, and year-end cash guidance revised Company does not expect to be cash flow neutral in 2023 Nasdaq compliance regained after 1-for-20 reverse split Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its fi

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/268055678 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the I

INBRIJA® (levodopa inhalation powder) Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q1 2023 net revenue of $12.6 million, a 15% decrease from Q1 2022; FAMPYRA royalty revenue of $2.9 million 2023 financial guidance reaffirmed Agreement with Chance Pharmaceuticals to commercialize INBRIJA in China Tom Burns, Chief Financial Officer of XOMA, to be candidate for Board of Directors at 2023 Annual Meeting of Stockholders; Jeff Randall to rotate off the Board Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/539980595 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the Inv

INBRIJA® (levodopa inhalation powder) 2022 U.S. net revenue of $28.0MM and ex-U.S. net revenue of $2.9MM; Q4 2022 U.S. net revenue of $9.0MM AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2022 net revenue of $72.9MM and FAMPYRA royalty revenue of $11.7MM; Q4 2022 AMPYRA net revenue of $18.8MM Achieved AMPYRA and INBRIJA U.S. net revenue, cash, and adjusted OPEX1 guidance for 2022 Full-year 2023 guidance and long-term outlook provided Nasdaq Hearings Panel grants extension until June 20, 2023 Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022. "Acorda's operating and financial performa

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2022 update and financial results on Thursday, March 9 at 8:30 a.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/932428600 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be availabl

INBRIJA® (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA® (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 $16.5M award and royalty/supply relief in AMPYRA arbitration case Special Meeting of Stockholders scheduled for November 4, 2022 Company will not use shares for December 2022 interest payment on secured debt 2022 guidance reaffirmed, 2023 through 2027 guidance provided Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2022. "The AMPYRA arbitration ruling was a major milestone for Acorda, pr

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://event.on24.com/wcc/r/4001897/47AF8C7CC150301C8AFD48F0F7E389AF If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation wi

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its second quarter 2022 update and financial results on Thursday, August 4 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://event.on24.com/wcc/r/3856828/FE399D309F4271576686FDEB3CDCB6EB If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation wi

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its first quarter 2022 update and financial results on Wednesday, May 11 at 4:30 p.m. ET. To participate in the Webcast, please use the following pre-registration link: https://event.on24.com/wcc/r/3723569/6748F9A544568ED252317BCE137DC161 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. Once you have registered, you will receive a confirmation email with Webcast/Conference Call details. For the Webcast, you will receive an email 2 hours prior to the start of the call with the link to join. The presentation wi

AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue of $84.6 million AMPYRA Q4 2021 net revenue of $22.5 million INBRIJA® (levodopa inhalation powder) 2021 net revenue of $29.6 million; 22% increase over 2020 INBRIJA Q4 2021 net revenue of $10.4 million; 12% increase over Q4 2020 Total 2022 non-GAAP operating expense expected to be $110-$120 million1 AMPYRA 2022 net revenue expected to be $68 - $78 million Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2021. "In 2021, we achieved our top corporate priorities: growing INBRIJA's net revenue, achieving the top of our guidanc

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2021 update and financial results on Wednesday, March 9 at 4:30 p.m. ET. To participate in the Webcast, please use the following pre-registration link: To register for the Webcast, use the link below: https://event.on24.com/wcc/r/3574324/FBCD2A344DA8CA67AE95FA847DFD2756 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. Once you have registered, you will receive a confirmation email with Webcast/Conference Call details. For the Webcast, you will receive an email 2 hours prior to

Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a conference call and webcast in conjunction with its second quarter 2021 update and financial results on Thursday, August 5 at 4:30 p.m. ET. To participate in the Webcast/Conference Call, please use the following pre-registration links: To register for the Webcast, use the link below: https://event.on24.com/wcc/r/3195872/22BFB32FE404D8CBC8AF8A39FB338F0E To register for the Conference Call, use the link below: https://www.incommglobalevents.com/registration/q4inc/8344/acorda-provides-financial-and-business-update-for-second-quarter-2021/ **When registering, please type your phone number with no special characters** Once you have reg